



MONO PHARMACARE LIMITED

CIN:U24304GJ2022PLC136193

GST NO.: 24AAQCM2821E1ZN

To,

THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
NSE SYMBOL: MONOPHARMA

Dear Sir/Madam,

Sub: Submission of Unaudited Financial Results for the Half Year ended 30th September 2025, (Standalone and Consolidated) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we hereby submit the Unaudited Financial Results of the Company (Standalone and Consolidated) with Limited Review for the half year ended 30th September 2025, duly approved by the Board of Directors at its meeting held on 29th November, 2025.

The following documents are enclosed herewith:

- Outcome of Board Meeting as per Regulation 30 and other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- Statement of Unaudited Financial Results (Standalone) for the half year ended 30th September 2025 with Limited Review Report issued by the Auditors of the Company.
- Statement of Unaudited Financial Results (Consolidated) for the half year ended 30th September 2025 with Limited Review Report issued by the Auditors of the Company.

We request you to kindly take the same on record.

Yours faithfully,
For and on Behalf of
Mono Pharmacare Limited,

Mr, Panilam Lakhataria
Managing Director
DIN: 07659275

Enc: As above



MONO PHARMACARE LIMITED

CIN:U24304GJ2022PLC136193

GST NO.: 24AAQCM2821E1ZN

November 29, 2025

To,
THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
SYMBOL: MONOPHARMA

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), and with reference to our earlier intimation letter dated November 6, 2025, regarding the Board Meeting originally scheduled for November 14, 2025 and subsequently rescheduled to November 18, 2025, November 21, 2025 and November 28, 2025, we hereby inform you that the Meeting of the Board of Directors of the Company was held today on **Saturday, November 29, 2025**, at the registered office of the Company to consider the businesses as per the agenda circulated earlier.

1. Considered and approved the resignation of Mrs. Supal Panilam Lakhtariya from the position of Executive Director & her continuation as a Non-Executive Director of the Company.
2. Took note of and accepted the resignation of Mr. Archit Shah (DIN- 09737945) from the position of Executive Director of the Company.
3. Considered and approved Standalone unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2025.
4. Considered and approved Consolidated unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2025.

Kindly note that the meeting of the Board of Directors of the Company commenced at **11:00 a.m.** and concluded at **05.00 p.m.**

We request you to kindly take the same on record.

Thanking You,
FOR, MONO PHARMACARE LIMITED

PANILAM LAKHATARIYA
MANAGING DIRECTOR
DIN: 07659275

Enclosure: A/a

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Limited Review Report

Review Report to
The Board of Directors,
MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ("the Company") for the half year ended September 30, 2025, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KUMBHAT & CO LLP
Chartered Accountants
Firm Regn. No. S000162/001609S

Gaurang
Champakla
I Unadkat

Digitally signed by
Gaurang Champakla
Unadkat
Date: 2025.11.28
22:36:30 +05'30'

Gaurang C. Unadkat
Partner

Place: Mumbai
Dated: November 28, 2025

Mem.No. 131708
UDIN: 25131708BMIEFG5114

Statement of Standalone Financial Results for the period ended on September 30, 2025

		(Rs. in Lakhs)			
	Particulars	For the Half Year Ended			Year ended on
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operation	4937.20	3825.77	4438.32	8264.08
II	Other income	1.37	175.18	78.39	253.57
III	Total Revenue (I + II)	4938.57	4000.94	4516.71	8517.65
IV	Expenses				
	Purchase of Traded Goods	4302.92	3783.00	4326.19	8109.19
	(Increase)/Decrease in Stock	321.45	-303.59	-376.13	-679.72
	Employee Benefits Expenses	172.09	147.56	118.74	266.30
	Finance Cost	71.33	64.92	59.34	124.27
	Depreciation and Amortisation Cost	3.89	5.18	3.17	8.36
	Other expenses	65.05	207.06	104.88	311.94
	Total Expenses	4936.73	3904.13	4236.19	8140.33
V	Profit before tax Extraordinary and Exceptional Items (III - IV)	1.85	96.81	280.51	377.32
VI	Exceptional Items	-	-	-	-
VII	Extraordinary Items And Tax (V- VI)	-	-	-	-
VIII	Profit Before Tax	1.85	96.81	280.51	377.32
IX	Tax Expenses				
	(1) Current Tax	0.46	19.60	52.00	71.60
	(2) Deferred Tax	-0.93	-2.52	-0.78	-3.30
X	Profit (Loss) for the Period	2.31	79.73	229.29	309.02
XI	Earning per Equity share :				
	(1) Basic	0.01	0.45	1.30	1.75
	(2) Diluted	0.01	0.45	1.30	1.75

Notes:

1.The above results were reviewed and recommended by the Audit Committee, at its meeting held on **28th November,2025** for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2.The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.

3.Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable.Secondary segmental reporting on the basis of the geographical location of the customers is as below :

Sr.No	Particulars	Half year ended on			
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	India	4937.20	3825.77	4438.32	8264.08
2	South Asian Countries	-	-	-	-
3	Rest of the World	-	-	-	-
	Total	4937.20	3825.77	4438.32	8264.08

4.The financial Results have been prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The Company has not paid the Income Tax liabilities of Rs. 43.72 lakhs for A.Y. 2024-2025 and Rs. 83.95 lakhs for 2025-26 of lakhs. However the provision has been made along-with the interest. The management is working on improving the cash flow management to ensure such non-compliance does not occur in future.

6. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

7.Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam S. Lakshatariya
Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Standalone Statement of Assets and Liabilities

(Rs. in Lakhs)

	Particulars	As at September 30th, 2025 (Unaudited)	As at March 31st, 2025 (Audited)
I.	EQUITY AND LIABILITIES		
(1)	Shareholders' Funds		
	(a) Share Capital	1766.86	1766.86
	(b) Reserve and surplus	1355.37	1353.06
		3122.23	3119.92
(2)	Non-current liabilities		
	(a) Long -term borrowings	1459.32	1354.56
	(b) Long -term Provisions	10.55	8.38
		1469.87	1362.94
(3)	Current Liabilities		
	(a) Short Term Borrowings	1070.55	1014.72
	(b) Trade Payables	2613.73	932.29
	(c) Other Current Liabilities	156.60	88.71
	(d) Short- term Provisions	85.28	88.23
		3926.17	2123.95
	TOTAL EQUITY AND LIABILITIES	8518.26	6606.81
II.	ASSETS		
(1)	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	17.76	21.32
	(ii) Intangible Assets	0.87	1.00
	(iii) WIP	1.80	1.80
	(b) Non-Current Investments	1071.38	1083.94
	(c) Deferred tax assets (Net)	5.39	4.47
	(d) Long-term loans and advances	0.75	0.75
		1097.95	1113.27
(2)	Current Assets		
	(a) Inventories	2457.58	2779.03
	(b) Trade Receivables	4614.89	1889.70
	(c) Cash and Cash Equivalents	54.98	11.11
	(d) Short Term Loans and Advances	291.93	768.39
	(e) Other Current Assets	0.92	45.30
		7420.30	5493.54
	TOTAL ASSETS	8518.26	6606.81

For and on behalf of the Board of Directors
Mono Pharmacare Limited


Panilam S. Lakhataria

Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Cash Flow statement for the period ended on September 30, 2025**(Rs. in Lakhs)**

Particulars	September 30, 2025	March 31, 2025
Cash flow from operating activities		
Profit/(loss) before tax	1.85	377.32
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	3.89	8.36
Finance Cost	71.33	124.27
Operating profit/(loss) before working capital changes	77.06	509.95
Movements in working capital:		
Increase/(decrease) in trade payables	1681.44	640.57
Increase/(decrease) in other current liabilities	67.89	9.24
Increase/(decrease) in short term provision	-2.94	61.27
Increase/(decrease) in short term borrowings	55.83	121.26
Decrease/(increase) in Inventories	321.45	-679.72
Decrease/(increase) in trade receivables	-2725.19	-145.49
Decrease/(increase) in short-term loans and advances	476.46	-540.77
Decrease/(increase) in other Current Assets	44.38	22.42
Cash generated from Operations	-3.63	-1.26
Less: Direct taxes paid	-0.46	-71.60
Net Cash from Operating Activities (A)	-4.09	-72.86
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-0.21	-18.18
Purchase of Investment	12.56	-724.45
Net cash flow from/(used in) investing activities (B)	12.35	-742.63
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	104.76	921.03
Payment / (Repayment) of Long term Loan advance	-	0.70
Long term Provision	2.17	4.09
Proceeds from issue of equity shares	-	-
Securities Premium on Allotment of Equity Shares	-	-
Utilised for IPO Expenses	-	-
Finance Cost	-71.33	-124.27
Net cash flow from/(used in) financing activities (C)	35.60	801.55
Net increase/(decrease) in cash and cash equivalents (A+B+C)	43.86	-13.94
Cash and cash equivalents at the beginning of the year	11.11	25.05
Cash and cash equivalents at the end of the year	54.98	11.11
Net increase/(decrease) in cash and cash equivalents	43.86	-13.94

For and on behalf of the Board of Directors

Mono Pharmacare Limited


Panilam S. Lakhariya

Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Limited Review Report

Review Report to
The Board of Directors,
MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ('the Statement') of **MONO PHARMACARE LIMITED** ("the Parent") ("the Company") and its Subsidiary Company for the half year ended September 30, 2025, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Consolidated Statement of Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KUMBHAT & CO LLP
Chartered Accountants
Firm Regn. No. S000162/001609S

Gaurang
Champakl
al Unadkat

Digitally signed by
Gaurang Champaklal
Unadkat
Date: 2025.11.28
22:35:54 +05'30'

Gaurang C. Unadkat
Partner

Place: Mumbai
Dated: November 28, 2025

Mem.No. 131708
UDIN: 25131708BMIEFH9692

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin- 380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Statement of Consolidated Financial Results for the period ended ended on September 30, 2025

(Rs. in Lakhs)

	Particulars	For the Half Year Ended			
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operation	6629.12	8118.22	8716.28	16834.49
II	Other income	1.40	93.61	4.27	97.88
III	Total Revenue (I + II)	6630.52	8211.83	8720.55	16932.38
IV	Expenses				
	Purchase of Traded Goods	5800.94	8060.31	8480.82	16541.13
	(Increase)/Decrease in Stock	377.85	-764.30	-545.06	-1309.35
	Employee Benefits Expenses	204.38	208.47	170.21	378.67
	Finance Cost	160.57	246.25	156.31	402.55
	Depreciation and Amortisation Cost	5.79	6.44	6.42	12.87
	Other expenses	68.85	323.58	136.64	460.22
	Total Expenses	6618.38	8080.75	8405.34	16486.08
V	Profit before tax Extraordinary and Exceptional Items (III - IV)	12.14	131.08	315.21	446.29
VI	Exceptional Items	-	-	-	-
VII	Extraordinary Items And Tax (V - VI)				
	Prior Period Expenses	-	-	-	-
VIII	Profit Before Tax	12.14	131.08	315.21	446.29
IX	Tax Expenses				
	(1) Current Tax	10.88	53.05	85.95	139.00
	(2) Deferred Tax	-0.93	-4.08	0.78	-3.30
X	Profit (Loss) for the Period	2.18	82.11	228.49	310.59
XI	Minority Interest	-0.13	-0.82	-0.75	-1.57
XII	Profit/(Loss) for the year after Taxes and Minority Interest	2.05	81.28	227.74	309.02
XIII	Earning per Equity share :				
	(1) Basic	0.01	0.45	1.30	1.75
	(2) Diluted	0.01	0.45	1.30	1.75

Notes:

1. The above results were reviewed and recommended by the Audit Committee, at its meeting held on **28th November, 2025** for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2. The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.

3. Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable. Secondary segmental reporting on the basis of the geographical location of the customers is as below :

Sr.No	Particulars	Half year ended on		Year ended on	
		September 30, 2025	March 31, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	India	6629.12	8118.22	8716.28	16834.49
2	South Asian Countries	-	-	-	-
3	Rest of the World	-	-	-	-
	Total	6629.12	8118.22	8716.28	16834.49

4. The financial Results have been prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The Company has not paid the Income Tax liabilities of Rs. 43.72 lakhs for A.Y. 2024-2025 and Rs. 83.95 lakhs for 2025-26 of lakhs. However the provision has been made along-with the interest. The management is working on improving the cash flow management to ensure such non-compliance does not occur in future.

6. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

7. Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam S. Lakhtaria
Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193

Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Consolidated Statement of Assets and Liabilities

(Rs. in Lakhs)

	Particulars	As at September 30th, 2025 (Unaudited)	As at 31st March, 2025 (Audited)
I.	EQUITY AND LIABILITIES		
(1)	Shareholders' Funds		
	(a) Share Capital	1766.86	1766.86
	(b) Reserve and surplus	1355.12	1353.06
	Minority Interest	3.64	3.52
		3125.62	3123.43
(2)	Non-current liabilities		
	(a) Long-term borrowings	2643.85	2596.14
	(b) Long-term Provisions	10.55	8.38
		2654.40	2604.52
(3)	Current Liabilities		
	(a) Short Term Borrowings	2855.73	2759.88
	(b) Trade Payables	2847.79	1879.83
	(c) Other Current Liabilities	354.46	482.20
	(d) Short-term Provisions	95.70	155.62
		6153.68	5277.55
	TOTAL EQUITY AND LIABILITIES	11933.70	11005.50
II.	ASSETS		
(1)	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	92.75	98.21
	(ii) Intangible Assets	0.87	1.00
	(iii) WIP	1.80	1.80
	(b) Non-Current Investments	-	-
	(c) Deferred tax assets (Net)	5.39	4.47
	(d) Long-term loans and advances	1.30	1.30
		102.11	106.77
(2)	Current Assets		
	(a) Inventories	5160.76	5538.61
	(b) Trade Receivables	6098.53	4188.75
	(c) Cash and Cash Equivalents	123.95	69.76
	(d) Short Term Loans and Advances	413.86	1013.92
	(e) Other Current Assets	34.49	87.68
		11831.59	10898.73
	TOTAL ASSETS	11933.70	11005.50

For and on behalf of the Board of Directors

Mono Pharmacare Limited

Panilam S. Lakhatariya

Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A, Krinkal Apartment, Opp. Mahalaxmi Temple, Paldi, Ahmedabad, Gujarat, Pin-380007

CIN: U24304GJ2022PLC136193


Website: www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Consolidated Cash Flow statement for the period ended on September 30, 2025

(Rs. in Lakhs)

Particulars	September 30, 2025	March 31, 2025
Cash flow from operating activities		
Profit/(loss) before tax	12.14	446.29
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	5.79	12.87
Finance Cost	160.57	402.55
Operating profit/(loss) before working capital changes	178.51	861.71
Movements in working capital:		
Increase/(decrease) in trade payables	967.95	911.32
Increase/(decrease) in other current liabilities	-127.74	362.86
Increase/(decrease) in short term provision	-59.92	93.37
Increase/(decrease) in short term borrowings	95.84	328.34
Decrease/(increase) in Inventories	377.85	-1309.35
Decrease/(increase) in trade receivables	-1909.78	-1029.72
Decrease/(increase) in short-term loans and advances	600.06	-542.43
Decrease/(increase) in other Current Assets	53.19	32.63
Cash generated from Operations	175.96	-291.27
Less: Direct taxes paid	-10.88	-139.00
Net Cash from Operating Activities (A)	165.08	-430.27
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-0.21	-22.63
Purchase of Investment	-	-
Net cash flow from/(used in) investing activities (B)	-0.21	-22.63
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	47.71	883.66
Payment / (Repayment) of Long term Loan advance	-	1.20
Long term Provision	2.17	4.09
Proceeds from issue of equity shares	-	-
Securities Premium on Allotment of Equity Shares	-	-
Finance Cost	-160.57	-402.55
Net cash flow from/(used in) financing activities (C)	-110.69	486.39
Net increase/(decrease) in cash and cash equivalents (A+B+C)	54.18	33.49
Cash and cash equivalents at the beginning of the year	69.76	36.27
Cash and cash equivalents at the end of the year	123.95	69.76
Net increase/(decrease) in cash and cash equivalents	54.18	33.49

For and on behalf of the Board of Directors
Mono Pharmacare LimitedPanilam S. Lakhataiya
Chairman & Managing Director

DIN: 07659275

Date: November 28, 2025

Place: Ahmedabad



MONO PHARMACARE LIMITED

CIN:U24304GJ2022PLC136193

GST NO.: 24AAQCM2821E1ZN

November 29, 2025

To,
NSE LIMITED
EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
SYMBOL: MONOPHARMA

Sub: Intimation for Change in designation of Mrs. Supal Panilam Lakhatriya (DIN: 07659180) from Executive Director to Non-Executive Director under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Ma'am,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in its meeting held on November 29, 2025, has approved the resignation of Mrs. Supal Panilam Lakhatriya (DIN: 07659180) as Executive Director however she shall continue to act as Non-Executive Director on the Board of the Company with effect from November 29, 2025 .

In compliance with SEBI Letter dated June 14, 2018 and NSE Circular, we wish to confirm that Mrs. Supal Panilam Lakhatriya (DIN: 07659180) has not been debarred from holding the office of Director by virtue of any other Authority.

The details required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No CIR/CFD/CMD/4/2015 dated 09/09/2015 are given in Annexure -I.

Kindly take a note of the same.

Thanking You,

Yours Faithfully

FOR, MONO PHARMACARE LIMITED

PANILAM LAKHATARIYA
MANAGING DIRECTOR
DIN: 07659275



Change in designation of Mrs. Supal Panilam Lakhatriya (DIN: 07659180) from Executive Director to Non-Executive Director on the Board of Directors of the Company

Sl. No.	Details of event(s) that need to be provided	Information of such event(s)
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Resignation of Mrs. Supal Panilam Lakhatriya (DIN: 07659180) from the position of Executive Director of the Company, due to pre occupation. However, she shall continue to serve on the Board as a Non-Executive Director of the Company.
2.	Date of appointment/ cessation (as applicable) & term of appointment;	Mrs. Supal Panilam Lakhatriya, who has been associated with the Company as an Executive Director since incorporation, has tendered her resignation from the position of Executive Director. The said resignation and continuation as a Non-Executive Director shall be effective subject to the approval of the Board of Directors at its meeting scheduled on November 29, 2025.
3.	Brief profile (in case of appointment);	Mrs. Supal Panilam Lakhatriya (DIN: 07659180), aged 40 years, has been associated with the Company since its inception. She holds a Bachelor of Science degree and has completed a Laboratory Technician Course. With over five years of experience as a Medical Representative at Krishna Medical Stores, she brings valuable knowledge of the pharmaceutical industry. She plays a key role in the Company's growth and oversees day-to-day operations across all departments.
4.	Disclosure of relationships between directors (in case of appointment of a director).	Mrs. Supal Panilam Lakhatriya is the wife of Mr. Panilam Lakhataiya, Managing Director of the Company.

Thanking You,

Yours Faithfully

FOR, MONO PHARMACARE LIMITED

PANILAM LAKHATARIYA
MANAGING DIRECTOR
DIN: 07659275

To,
Board of Directors,
Mono Pharmacare Limited
1A, Krinkal Appartment,
Opp. Mahalaxmi Temple, Paldi,
Ahmedabad, Gujarat, India, 380007

Subject: Resignation as Executive Director & Consent to act as Non-Executive Director

I, Supal Panilam Lakhataria, hereby tender my resignation from the position of Executive Director of Mono Pharmacare Limited due to my pre-occupation. However, I shall continue to serve on the Board of the company in the capacity of a Non-Executive Director.

I further confirm that I am not disqualified from being appointed as an Director under the provisions of the Companies Act, 2013..

Date: 05.11.2025
Place: Ahmedabad


SUPAL PANILAM LAKHATARIYA
DIN: 07659180



MONO PHARMACARE LIMITED

CIN:U24304GJ2022PLC136193

GST NO.: 24AAQCM2821E1ZN

Date: November 29, 2025

To,
Listing Department National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra- Kurla Complex, Bandra,
Mumbai-400051, Maharashtra.

Symbol: - MONOPHARMA

ISIN: INEOOIPO1012

Subject: Intimation regarding the resignation of Mr. Archit Shah(DIN: 09737945), Director in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (Listing Regulations'), we wish to inform you that, Mr. Archit Shah(DIN: 09737945), has tendered his resignation as the Director of the Company, with effect from close of business hours on Saturday, November 29, 2025, citing pre-occupation and other personal commitments.

The letter of resignation received from Mr. Archit Shah(DIN: 09737945), is enclosed herewith.

The information in regard to the abovementioned change in the Board composition in terms of Regulation 30 read with Schedule II - Para A (7B) of Part A of the Listing Regulations (as applicable) and SEBI Circular bearing Ref. No. CIR/CFD/CMD/4/2015 dated 9th September 2015 is enclosed herewith.

Please take on record the above information.

Yours faithfully,
For and on Behalf of
Mono Pharmacare Limited,

Mr, Panilam Lakhatariya
Managing Director
DIN: 07659275

Enc: As above



MONO PHARMACARE LIMITED

CIN:U24304GJ2022PLC136193 GST NO.: 24AAQCM2821E1ZN

Details of resignation of Mr. Archit Shah (DIN: 09737945) from the post of Director of the Company (Details as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023)

Sr. No.	Disclosure Requirements	Details
1.	Name of the Director	Mr. Archit Shah (DIN: 09737945)
2.	Reason for change viz. appointment , resignation, removal, death or otherwise	Resignation of Mr. Archit Shah (DIN: 09737945) as the Director of the Company, with effect from close of business hours on November 29, 2025
3.	Date of appointment /cessation	Close of business hours on November 29, 2025
4.	Terms of appointment/re-appointment	Not applicable
5.	Brief profile of director (in case of appointment)	Not applicable
6.	Disclosure of relationship between directors inter-se	Not applicable
7.	Letter of Resignation along with detailed reason for resignation	Enclosed herewith

NOTICE OF RESIGNATION

To,
The Board of Directors,
MONO PHARMACARE LIMITED
1A, Krinkal Appartment Opp. Mahalaxmi Temple, Paldi,
Ahmedabad-380007, Gujarat, India.

Date: 05.11.2025

Dear Sir/Madam,

Sub: Resignation from the post of Directorship of the Company.

I, **ARCHIT SHAH (DIN: -09737945)**, Director of your Company, due to personal reason and other commitments, I do hereby tender my resignation from the Directorship of the Company.

Kindly accept this letter as my resignation from the post of Director of the Company. Also process and settle the accounts with pending fees payable if any.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies (ROCs), to that effect and necessary submission to the stock exchange.

Thanking You.

Yours faithfully,

A.S. Shah

ARCHIT SHAH
DIN - 09737945